Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT02643147
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 170 participants
- Registry
-
NCT02643147
-
- Other papers using this trial's data
- Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT02643147. Randomized; single masking; primary purpose treatment. Start 2015-01 (actual); primary completion 2017-01-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)
- Acronym
- IMPROVE-HF
- Condition
- Heart Failure
- Intervention (Drug)
- CA125 guided strategy
- Intervention (Drug)
- CA125 guided strategy
- Intervention (Drug)
- Conventional Strategy
- Lead sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Record details
- Record id
cardio:ct-nct02643147- Content hash
3221b391af372c6cf46bcc28027a9550fd05cba3f2ca9d2f9141c1ca17959c05